Earnings summaries and quarterly performance for PLIANT THERAPEUTICS.
Executive leadership at PLIANT THERAPEUTICS.
Board of directors at PLIANT THERAPEUTICS.
Research analysts covering PLIANT THERAPEUTICS.
Recent press releases and 8-K filings for PLRX.
Pliant Therapeutics Updates on 10-10-95 Phase 1 Study and Program Advancement
PLRX
New Projects/Investments
Guidance Update
- Pliant Therapeutics (PLRX) announced updated Phase 1 study data for its drug 10-10-95, demonstrating a durable response in heavily pretreated patients, with four responders including one complete responder after a median of 15 months on treatment.
- The drug 10-10-95 was well tolerated, with mild to moderate rash as the most frequent adverse event, leading to only one discontinuation.
- The company plans to advance the 10-10-95 program to Part 2 of the Phase 1b study, focusing on specific tumor types, beginning with non-small cell lung carcinoma, and anticipates data in 2027.
- Pliant Therapeutics reported having cash through 2028, providing ample runway for its current plans.
- The oncology program with 10-10-95 is now the lead asset for the integrin platform company, which also has earlier-stage programs in targeted drug delivery of siRNAs.
Dec 4, 2025, 5:30 PM
Pliant Therapeutics (PLRX) Provides Positive 10-10-95 Phase 1 Data Update and Outlines Next Steps
PLRX
New Projects/Investments
- Pliant Therapeutics (PLRX) presented updated Phase 1 data for its oncology program, 10-10-95, showing a durable response over a median of 15 months in heavily pretreated patients, including one complete responder. The drug was well-tolerated, with mild to moderate rash as the most frequent adverse event.
- The company announced it will advance the 10-10-95 program to Part Two of the Phase 1b study, initially targeting non-small cell lung carcinoma and evaluating the 1,000-milligram BID dose. Data from this next phase is anticipated in 2027.
- Pliant also highlighted its broader integrin platform, with new early-stage programs in siRNA delivery to muscle cells and adipocytes, with initial in vivo data expected to be disclosed in 2026.
- Financially, Pliant Therapeutics reports a strong position with a cash runway through 2028.
Dec 4, 2025, 5:30 PM
Pliant Therapeutics Presents Positive Phase 1 Data for PLN-101095 and Financial Outlook
PLRX
New Projects/Investments
Guidance Update
- Pliant Therapeutics is developing PLN-101095, an oral αvβ8 / αvβ1 inhibitor, for ICI-resistant tumors, which demonstrated 4 clinical responders (1 complete response and 3 partial responses, one unconfirmed) at the three highest Phase 1 doses in heavily pre-treated patients.
- Clinical responders for PLN-101095 have shown a durable response with a median time on treatment of 15 months to date, and the drug was well tolerated in the Phase 1 study.
- Pliant's strong cash position is projected to fund operations through 2028.
Dec 4, 2025, 5:30 PM
Pliant Therapeutics Reports Q3 2025 Financial Results and Provides Corporate Update
PLRX
Earnings
New Projects/Investments
Debt Issuance
- Pliant Therapeutics reported a net loss of $26.3 million for the third quarter of 2025, an improvement from $57.8 million in the prior-year quarter, primarily due to reduced research and development and general and administrative expenses.
- Research and development expenses decreased to $17.9 million in Q3 2025 from $47.8 million in Q3 2024, and general and administrative expenses decreased to $10.3 million from $14.3 million.
- As of September 30, 2025, the company held $243.3 million in cash, cash equivalents, and short-term investments.
- Enrollment is complete for the Phase 1 open-label trial of the oncology program (PLN-101095), with data from all five dose cohorts anticipated by the end of 2025.
- In October, Pliant Therapeutics completed a voluntary prepayment of all outstanding principal and associated costs under its loan agreement with Oxford Finance LLC.
Nov 6, 2025, 9:09 PM
Pliant Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
PLRX
Earnings
Guidance Update
- Pliant Therapeutics reported a net loss of $26.3 million for the third quarter of 2025, a decrease from $57.8 million in the prior-year quarter, with research and development expenses falling to $17.9 million.
- As of September 30, 2025, the company held $243.3 million in cash, cash equivalents, and short-term investments.
- The Phase 1 oncology program (PLN-101095) has completed enrollment, with data from all five dose cohorts expected by the end of 2025.
- Close-out activities for the BEACON-IPF Phase 2b/3 clinical trial are projected to be completed in the fourth quarter of 2025.
- In October, the company completed a voluntary prepayment of all outstanding principal, accrued and unpaid interest, fees, costs, and expenses under its March 2024 Loan Agreement with Oxford Finance LLC.
Nov 6, 2025, 9:05 PM
Palvella Therapeutics Receives Second Year of FDA Orphan Products Grant Funding
PLRX
New Projects/Investments
Product Launch
- Palvella Therapeutics has received the second year of funding from its FDA Office of Orphan Products Development grant, providing up to $2.6 million in non-dilutive funding over its 4-year term.
- This grant supports the ongoing Phase 3 SELVA trial of QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations.
- The SELVA trial has exceeded its enrollment target, enrolling 51 subjects.
- Top-line data from the SELVA trial is expected in the first quarter of 2026, with a New Drug Application (NDA) submission planned for the second half of 2026.
- QTORIN™ rapamycin has been granted Breakthrough Therapy, Orphan Drug, and Fast Track designations by the FDA.
Oct 13, 2025, 11:30 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more